Oracle (ORCL) PT Raised to $235 at Oppenheimer, "reiterate ORCL as our top pick"

Oppenheimer analyst Brian Schwartz raised the price target on Oracle (NYSE: ORCL) to $235.00 (from $210.00) while maintaining a Outperform rating.

The analyst commented: "We reiterate ORCL as our top pick and raise our PT to $235 from $210 as we see positive developments during the current quarter that lend support to our superior EPS compounder thesis. Specifically, the strong technology infrastructure spending revealed in the 1Q reports from Oracle's largest customers, partners, and suppliers combined with a significant restructuring announcement on March 31 (i.e., ~30K employees/18% of the workforce) bode well for potential upside in the F4Q26 results next month and bolster the medium-term financials guidance, in our view. Furthermore, we expect solid bookings growth in F4Q26 from OpenAI, Meta, NVIDIA and federal government commitments, Microsoft outsourcing its lower margin training business to Oracle, and demand uplift from the positive seasonality for the broader Oracle product portfolio."

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• Alphabet (GOOGL) call put ratio 1.6 calls to 1 put with a focus on June 22 weekly calls as share price down 6%
• Devon Energy (DVN) PT Lowered to $67 at Wolfe Research: Activist Toms interest positive